معرفی
Hans Clevers is a renowned scientist and currently serves as Head of Pharma Research and Early Development (pRED) at Roche (Basel, Switzerland) since 2022. He holds a professorship in Molecular Genetics at the University Utrecht, Netherlands. Previously, he was Director and President of the Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, and the Princess Maxima Center for pediatric oncology.
- Education: MD and PhD from University Utrecht, Netherlands (not specified exact years).
- Affiliations: Roche pRED, Hubrecht Institute (advisor/guest researcher), Royal Netherlands Academy of Arts and Sciences.
Research Interests
Clevers' work focuses on molecular mechanisms of tissue development and cancer, particularly the Wnt signaling pathway, stem cell biology, and organoid technology. His group pioneered 3D organoid cultures, revolutionizing disease modeling and drug discovery. Key achievements include:
- Characterization of LGR5 stem cells and Wnt signaling in colon cancer.
- Development of organoid models for cancer, gut biology, and infectious diseases (e.g., SARS-CoV-2).
Awards & Honors
Clevers has received numerous accolades, including the Breakthrough Prize in Life Sciences, membership in multiple national academies (Netherlands, USA, UK, France), and knighthoods. His work bridges academia and industry, driving translational research in biomedicine.
Labs & Teams
As former group leader at Hubrecht, his team (now the Organoid Group) continues groundbreaking research. Collaborations with Roche and other institutions emphasize clinical applications of organoids.
